X
Description
Xspray Pharma AB is a Swedish pharmaceutical company based in Solna developing improved versions of protein kinase inhibitors (PKIs) for cancer treatment, using its patented HyNap® platform. HyNap is an atomic layer deposition technology that improves bioavailability through amorphous particle stabilization with high drug load. Portfolio includes Dasynoc (dasatinib, leukemia/ALL), XS003 (nilotinib), XS008 (axitinib) and XS015 (cabozantinib). Has resubmitted FDA application for Dasynoc. Listed on Nasdaq Stockholm.